Journal of Oral Oncology / 2014 / Article / Tab 2 / Clinical Study
Head and Neck Solitary Extramedullary Plasmacytoma Table 2 Characteristics and treatment outcomes of 565 patients with extramedullary solitary plasmacytoma of the head and neck in 26 reported series and the present study [
3 –
7 ,
10 –
30 ].
Authors (references) Pts’ number MCPS M/F Median age RT dose (Gy) LC (%) PTMM (%) OS rate Bachar et al. [24 ] 68 SNT 41/27 — 35 — 23 76% (5 yr) Bolek et al. [29 ] 10 — — — 43.2 100 54 80% (15 yr) Chao et al. [11 ] 14 SNT, NPX 14/0 59 45 100 31 54% (10 yr) Creach et al. [10 ] 18 — 16/2 64 50.4 100 11 31–82% (5 yr) Galieni et al. [12 ] 16 — — 54 — 92 15 78% (15 yr) Hotz et al. [27 ] 14 — — — — 86 14 — Jyothirmayi et al. [3 ] 7 SNT 6/1 58 40 85 42 57% Kapadia et al. [13 ] 20 SNT, NPX 16/5 59 40–45 85 20 85% (10 yr) Kilciksiz et al. [14 ] 23 Oral cavity 14/9 47 50 95 17.4 89% (10 yr) Krause et al. [15 ] 8 NPX — 61 48 100 25 100 (10 yr) Liebross et al. [28 ] 19 — — — 50 95 44 50% (5 yr) Mendenhall et al. [4 ] 20 SNT, NPX 17/3 62 40–50 100 30 80% (5 yr) Michalaki et al. [16 ] 10 SNT 6/4 55 40–50 100 20 50% (5 yr) Miller et al. [17 ] 18 SNT, NPX 12/6 50.4 45–50 — 11 — Ozsahin et al. [26 ] 52 SNT — — 40 74 36 72% (5 yr) Reed et al. [23 ] 23 SNT — 56 45 92 30 85% (5 yr) Sasaki et al. [18 ] 67 SNT 43/24 64 50 87 12 56% (10 yr) Shih et al. [5 ] 10 — 9/1 63 54 70 20 100% (10 yr) Strojan et al. [25 ] 22 Oropharynx 17/5 — 54 100 8 61% (10 yr) Suh et al. [19 ] 13 SNT 8/5 52 50 77 15 87% (10 yr) Susnerwala et al. [7 ] 25 SNT 23/2 68 38.9 79 8 59% (5 yr) Tournier-Rangeard et al. [21 ] 17 SNT, NPX 14/3 62 52.6 73 31 63.4% (10 yr) Tsang et al. [6 ] 14 SNT, NPX — — 35 93 84 65% (10 yr) Yang et al. [20 ] 23 SNT 17/6 49 — — — — Yang et al. [30 ] 8 — — — 35 — 12.5 — Zhou et al. [22 ] 12 SNT 10/2 57 — — — 53% (5 yr) Present study 13 SNT, NPX 10/3 52 49 89 15 74.1% (10 yr) Total 564 SNT 293/108 58 44.5 88 23 70
Pts’ number: patients number, MCST: most common primary sites, M/F: male/female, LC: local recurrence, PTMM: progressed to multiple myeloma, OS: overall survival, SNT: sinonasal tract, NPX: nasopharynx, LRX: larynx, and NC: nasal cavity.